In a cutting-edge research project focused on catalysis, a team of chemists is developing a novel coordination complex, 'Catalyst C', featuring a transition metal center. This catalyst is designed for a specific organic transformation in the synthesis of a pharmaceutical compound. The development of 'Catalyst C' involves several key considerations to enhance its catalytic activity and selectivity. The sequence of the catalyst development is as follows: 'Catalyst C' is synthesized with a rare transition metal at its core, known for its unique electronic and redox properties. The metal center is coordinated with a specially designed ligand that introduces asymmetry to create a chiral environment around the metal. The catalyst is then tested in a reaction involving the asymmetric hydrogenation of an unsaturated organic substrate. Modifications are made to the ligand structure to fine-tune the electronic environment of the metal center, aiming to optimize the yield and enantioselectivity of the reaction. Based on this sequence, what is the primary challenge or objective in the development of 'Catalyst C' for use in pharmaceutical synthesis? Options: A. Achieving high thermal stability of the catalyst B. Maximizing the turnover number and frequency of the catalyst C. Enhancing the enantioselectivity and yield of the target reaction D. Reducing the overall cost and increasing the availability of the catalyst Hints: Consider the implications of each step in the catalyst development process and how they contribute to the performance in asymmetric synthesis. Reflect on the importance of chiral environments, electronic properties, and ligand design in catalysis, particularly for pharmaceutical applications. Think about the primary goals in catalysis for pharmaceutical synthesis, focusing on efficiency, selectivity, and the creation of chiral centers.